Puma Biotechnology Inc. (NYSE:PBYI) has been given a $89.00 target price by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 36.59% from the stock’s current price.

PBYI has been the subject of a number of other research reports. Stifel Nicolaus raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and increased their target price for the company from $61.00 to $88.00 in a research report on Wednesday. Vetr raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating and set a $42.54 target price for the company in a research report on Tuesday, May 31st. Credit Suisse Group AG reissued a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 12th. Citigroup Inc. set a $88.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research report on Friday, August 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $60.94.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Shares of Puma Biotechnology (NYSE:PBYI) traded up 4.80% during trading on Tuesday, reaching $68.29. 2,075,298 shares of the company were exchanged. Puma Biotechnology has a one year low of $19.74 and a one year high of $95.18. The company’s market capitalization is $2.22 billion. The firm’s 50 day moving average price is $54.72 and its 200 day moving average price is $39.31.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/puma-biotechnology-inc-pbyi-given-a-89-00-price-target-at-jpmorgan-chase-co.html

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.18) by $1.01. Equities research analysts forecast that Puma Biotechnology will post ($8.12) earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Northern Capital Management LLC boosted its position in shares of Puma Biotechnology by 1.2% in the second quarter. Northern Capital Management LLC now owns 16,288 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 190 shares in the last quarter. Profund Advisors LLC boosted its position in shares of Puma Biotechnology by 1.6% in the second quarter. Profund Advisors LLC now owns 12,706 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 202 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Puma Biotechnology by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 465 shares in the last quarter. BlackRock Group LTD boosted its position in shares of Puma Biotechnology by 2.1% in the second quarter. BlackRock Group LTD now owns 30,255 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 633 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC boosted its position in shares of Puma Biotechnology by 3.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 34,025 shares of the biopharmaceutical company’s stock worth $1,014,000 after buying an additional 980 shares in the last quarter. Institutional investors own 97.53% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.